Skip to content

PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT Study

Prognostic Value of Photon-Counting Detector CT-Derived High-Risk Coronary Plaque Features for Predicting Major Adverse Cardiovascular Events: a Prospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07822737
Acronym
PREDICT
Enrollment
500
Registered
2026-09-16
Start date
2025-01-18
Completion date
2030-12-30
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Photon-Counting Computed Tomography, Plaque

Keywords

Photon-Counting Computed Tomography, Coronary Artery Disease, High risk plaque

Brief summary

This prospective cohort study aims to determine whether high-risk coronary plaques identified by novel Photon-Counting Detector CT (PCCT) independently predict future major adverse cardiovascular events (MACE). Participants will be followed for MACE and revascularization. The primary hypothesis is that the incidence of MACE is significantly higher in patients with PCCT-defined high-risk plaque than in those without. Additionally, patients will undergo Optical Coherence Tomography (OCT) and angiography within a month after PCCT; PCCT results will be compared with OCT in a cross-sectional analysis, and diagnostic performance will be evaluated against follow-up data.

Detailed description

Photon-Counting Detector CT (PCCT) enables improved spatial resolution and spectral tissue characterization, allowing non-invasive detection of high-risk coronary plaque (HRP) features such as low-attenuation plaque (\<30 HU), positive remodeling (index ≥1.1), spotty calcification, and the napkin-ring sign. The presence of ≥2 of these features defines a PCCT-detected high-risk plaque. Optical Coherence Tomography (OCT), an invasive high-resolution imaging tool, defines HRP by thin-cap fibroatheroma (fibrous cap thickness \<65 μm, lipid arc \>90°) and other vulnerable features. While OCT provides detailed information on plaque vulnerability, it is invasive and limited to selected vessels. The prognostic significance of PCCT-defined HRP, and its diagnostic agreement with OCT, remain to be fully established. This prospective, single-centre study will enroll patients with acute or stable coronary syndromes who are scheduled for clinically indicated invasive coronary angiography and OCT evaluation of at least one native coronary artery. All participants will first undergo a dedicated contrast-enhanced PCCT coronary angiogram. Within 30 days after PCCT, participants will undergo invasive coronary angiography with OCT imaging. Thus, OCT is systematically acquired after the CT, allowing a cross-sectional diagnostic comparison where PCCT findings are evaluated against the OCT reference. Both imaging datasets will be analyzed by independent core laboratories blinded to each other's results and to clinical data. The study has two integrated components: 1. Prognostic component - The primary objective is to assess whether the presence of PCCT-defined HRP independently predicts the 2-year incidence of MACE (cardiovascular death, non-fatal myocardial infarction, hospitalization for unstable angina requiring urgent revascularization). The primary hypothesis is that MACE rate is significantly higher in patients with PCCT-HRP than in those without. 2. Cross-sectional diagnostic comparison - Using OCT as the invasive reference, the diagnostic performance of PCCT for identifying high-risk plaque will be determined. Per-patient and per-lesion sensitivity, specificity, positive and negative predictive values, and overall accuracy of PCCT will be calculated and compared with OCT-derived high-risk plaque classification. Participants will be followed prospectively for MACE and unplanned revascularization over 24 months.

Interventions

None listed

Sponsors

Beijing Chao Yang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Scheduled for clinically indicated, non-emergent invasive coronary angiography * Provision of written informed consent and willingness to comply with long-term follow-up

Exclusion criteria

* Estimated glomerular filtration rate \<45 mL/min/1.73 m² * Known allergy to iodinated contrast media * Pregnancy or breastfeeding * Persistent atrial fibrillation or other arrhythmia precluding adequate ECG-gated CT acquisition * Body mass index \>40 kg/m² * Target vessel with a previously implanted stent * Life expectancy \<2 years or any condition that, in the opinion of the investigator, makes follow-up unlikely or participation inappropriate

Design outcomes

Primary

MeasureTime frameDescription
Incidence of major adverse cardiovascular events (MACE)Up to 24 monthsIncidence of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and hospitalization for unstable angina requiring urgent revascularization, stratified by the presence versus absence of PCCT-defined high-risk plaque.

Secondary

MeasureTime frameDescription
Per-lesion MACEUp to 24 monthsPer-lesion hazard ratio of MACE for PCCT-defined HRP and OCT-defined HRP, adjusted for baseline clinical risk factors
Myocardial infarctionUp to 24 monthsTime to first non-fatal myocardial infarction

Countries

China

Contacts

CONTACTBin Tu, MD.PhD
dr_bintu@163.com+8618810682692

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026